Partners on lung cancer immunotherapy
INGELHEIM, Germany & RIDGEFIELD, Conn.—Boehringer Ingelheim and CureVac have jointly announced an exclusive global license and development collaboration centered on CureVac’s CV9202, a novel investigational therapeutic mRNA vaccine being developed for lung cancer. The therapeutic, a combination of mRNA molecules that code for six antigens that are overexpressed in lung cancer, is engineered to induce an immune response against tumors. Per the agreement, CureVac will receive €35 million (approximately $45 million), with the potential for up to €430 million (approximately $556 million) in milestone payments, as well as sales royalties. Boehringer Ingelheim will receive exclusive global rights to develop and commercialize CV9202, and will begin clinical investigation of the compound in at least two different lung cancer settings, in combination with afatinib in patients with advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer (NSCLC) and in combination with chemo-radiation therapy in patients with unresectable stage III NSCLC.